Treatment of swelling of voice box with Unani medicine Habb-e Khunaq

Clinical validation of Unani pharmacopoeial formulation Habb-e Khunaq in Waram e Hanjara (Laryngitis)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/049200

Enrollment

220

Registered

2023-01-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J040- Acute laryngitis

Interventions

Intervention1: Habb-e-Khunaq: 3 tablets thrice daily orally with water for one week Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-60 years. 2. Presence of all of the following signs and symptoms of Waram-i-Hanjara (Laryngitis) Hoarseness. Weak voice or discomfort in speaking-dysphonia Tickling sensation and rawness in your throat Globus pharyngeus (feeling of a lump in the throat) Sore throat Dry throat Dry cough

Exclusion criteria

Exclusion criteria: 1. Loss of voice (aphonia) 2. Dysphagia, odynophagia 3. History of fever morethan 380 C 4. Known cases of Renal/ Hepatic/ Cardiac ailments/ Diabetes mellitus 5. Pregnant and lactating women 6. Chronic alcoholic and smokers 7. Gastro esophageal reflux 8. Spasmodic dysphonia 9. Reflux laryngitis, Chronic allergic laryngitis, Epiglottitis 10. Known case of any type of Neoplasms

Design outcomes

Primary

Measure	Time frame
The efficacy of the study drug will be assessed on the basis of improvement in Hoarseness and other symptoms. Hoarsness will be assessed by GRBAS scale. The other symptoms (Weak voice or discomfort in speaking-dysphonia, Tickling sensation and rawness in throat, Globus pharyngeus (feeling of a lump in the throat), Sore throat, Dry throat, Dry cough) will be assessed using the Visual Analogue Scale (VAS).Timepoint: At baseline, 3rd and 7th day	—

Measure

Time frame

The efficacy of the study drug will be assessed on the basis of improvement in Hoarseness and other symptoms. Hoarsness will be assessed by GRBAS scale. The other symptoms (Weak voice or discomfort in speaking-dysphonia, Tickling sensation and rawness in throat, Globus pharyngeus (feeling of a lump in the throat), Sore throat, Dry throat, Dry cough) will be assessed using the Visual Analogue Scale (VAS).Timepoint: At baseline, 3rd and 7th day

—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessment Timepoint: Investigations will be done at baseline and end of treatment	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026